BXRX
Baudax Bio Inc
-52.79%
$3.41 - $1.61
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
Analysts have set a price target of $3 for ENSC... See more
Jan, 24, 2023
Our team of ANALYSTS hit the BULLSEYE by CALLING O... See more
HTGM
HTG Molecular Diagnostics Inc
-37.26%
$4.67 - $2.93
Feb 7th 2023 - Mar 21st 2023
Jan, 23, 2023
Micro float (~600K), great company with increase i... See more
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K flo... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Dec, 30, 2022
The analyst comments "TGTX stock is up >15... See more
Dec, 30, 2022
Ignorant analyst are a plus.
Mar, 16, 2023
Analysts have set a price target of $3 for ENSC's stock, making it a strong buy for those looking to invest in the future of the industry🔥🚀 Also following: $THMO $HUBC $TRKA $BXRX
Jan, 24, 2023
Our team of ANALYSTS hit the BULLSEYE by CALLING OUT $GMBL and raking in an EXHILARATING 87% GAIN!
Oct, 28, 2022
$BXRX the analysts are really liking this stock right now.
Jan, 23, 2023
Micro float (~600K), great company with increase in YoY revenue, and high analyst price targets.
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 30, 2022
Ignorant analyst are a plus.
Dec, 30, 2022
This stock would go far beyond analysts Price Target.
Dec, 30, 2022
$TGTX , absolutely amazing….Scumbag’s Bank of America analyst rated TG today as underperform $6….total joke….I guess the analyst is waiting for FDA approval…LOL ….stick to loans and mortgages….very bullish TG community Longs….
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,